rang
opportunist
pathogen
cancer
transplant
patient
continu
increas
new
treatment
modal
form
immunosuppress
follow
transplant
improv
surviv
underli
diseas
lead
prolong
immunosuppress
increas
risk
infect
nice
guidelin
manag
neutropen
sepsi
avail
arous
controversi
particularli
recommend
quinolon
prophylaxi
highrisk
patient
group
addit
neutropenia
longterm
defect
cellmedi
immun
expos
patient
risk
chronic
viral
protozo
fungal
infect
advanc
diagnost
techniqu
potenti
improv
manag
limit
unnecessari
empir
treatment
allow
move
toward
diagnosisdriven
strategi
howev
interpret
clinic
valid
util
assay
difficult
particularli
lowpreval
infect
posit
predict
valu
diagnost
test
like
low
prompt
empir
antibacteri
therapi
still
indic
neutropen
patient
well
recogn
cancer
transplant
patient
immunocompromis
virtu
underli
diseas
chemotherapeut
radiat
treatment
need
ongo
immunosuppress
classic
neutropen
patient
consid
risk
bacteri
fungal
infect
predomin
period
howev
increas
use
novel
aggress
chemotherapi
immunosuppress
agent
includ
biolog
responsemodifi
agent
monoclon
antibodi
led
grow
popul
patient
deficit
cellmedi
immun
cmi
expos
risk
seriou
viral
fungal
infect
may
prolong
tabl
number
death
neutropen
sepsi
doubl
offic
nation
statist
neutropen
sepsi
patient
anticanc
treatment
defin
neutrophil
count
equal
lower
litr
either
temperatur
higher
c
sign
symptom
consist
clinic
signific
sepsi
mortal
untreat
neutropen
sepsi
rang
empir
therapi
immunocompromis
patient
essenti
sever
common
pitfal
manag
suspect
infect
follow
concept
empir
treatment
appli
patient
sourceorgan
identifi
frequent
misunderstood
patient
infiltr
chest
xray
obviou
line
softtissu
infect
pathogen
alreadi
isol
receiv
target
therapi
determin
nation
guidelin
empir
neutropen
fever
regimen
differenti
uncompl
neutropen
fever
lifethreaten
neutropen
sepsi
alway
made
term
sometim
use
interchang
sepsi
requir
addit
rapid
intervent
appropri
care
bundl
sepsi
manag
definit
respons
antibiot
often
determin
incorrectli
resolut
fever
unrealist
expect
fever
settl
rapidli
wherea
realiti
durat
fever
document
bacteri
infect
day
lead
inappropri
addit
andor
switch
antimicrobi
marker
respons
concentr
clinic
variabl
includ
reduc
fever
haemodynam
stabil
normal
acut
phase
respons
marker
respons
determin
sole
rapid
defervesc
fever
histor
immunocompromis
patient
succumb
gramneg
septicaemia
advent
activ
antibiot
especi
antipseudomon
penicillin
combin
frequent
use
longterm
intravascular
access
devic
led
chang
spectrum
organ
rise
gramposit
infect
due
particularli
coagulaseneg
staphylococci
recent
pendulum
swung
back
reemerg
gramneg
organ
produc
extend
spectrum
betalactamas
carbapenemas
result
infect
multiresist
organ
recent
nice
guidanc
attempt
standard
practic
earli
recognit
rapid
intervent
sepsi
crucial
must
rememb
sever
infect
may
present
hypothermia
monotherapi
extendedspectrum
betalactam
agent
shown
equival
less
toxic
aminoglycosid
combin
sever
metaanalys
recommend
guidelin
concern
regard
analys
remain
compar
differ
blactam
agent
differ
studi
take
account
chang
spectrum
diseas
time
concern
address
mix
treatment
analysi
demonstr
benefit
monotherapi
ureidopenicillin
piperacillin
tazobactam
tazocin
treatment
associ
lowest
mortal
although
necessarili
infecti
mortal
affect
year
studi
empir
use
glycopeptid
discourag
howev
decid
initi
empir
therapi
import
consid
clinic
microbiolog
find
combin
therapi
may
still
indic
centr
high
incid
resist
undertak
risk
assess
key
nice
recommend
outlin
practic
point
current
nice
guidanc
go
beyond
initi
empir
phase
cover
refractori
fever
mani
problem
aris
patient
unrespons
fever
fungal
andor
viral
infect
may
suspect
empir
antifung
therapi
still
consid
mani
standard
care
patient
refractori
fever
inevit
result
massiv
overus
costli
potenti
toxic
antifung
drug
patient
actual
invas
fungal
diseas
solid
organ
transplant
incid
invas
fungal
diseas
ifd
vari
lowest
renal
transplant
highest
small
bowel
transplant
infect
caus
candida
speci
except
lung
transplant
patient
aspergillosi
caus
invas
diseas
tracheobronch
patient
liver
transplant
patient
often
consid
high
risk
mould
infect
incid
rel
low
unless
specif
risk
factor
retransplant
renal
failur
present
haematolog
stem
cell
transplant
patient
azol
prophylaxi
candida
wide
use
invas
aspergillosi
major
ifd
seen
rate
rang
less
improv
radiolog
techniqu
introduct
biomark
antigen
test
polymeras
chain
reaction
allow
move
away
empir
therapi
toward
target
preemptiv
approach
infect
associ
defect
cellmedi
immun
addit
neutropenia
patient
undergo
treatment
malign
frequent
also
lymphopen
recogn
nearli
half
centuri
ago
concomit
lymphopenia
doubl
risk
sever
infect
use
immunosuppress
prevent
reject
graftversushost
diseas
increas
use
monoclon
antibodi
therapi
rituximab
alemtuzumab
campath
profound
longlast
effect
cmi
rang
emerg
pathogen
includ
acanthamoeba
algal
prototheca
infect
continu
grow
despit
advanc
treatment
hiv
diseas
pneumocysti
infect
increas
seen
group
previous
consid
high
risk
infect
posttransplant
lymphoprolif
disord
ptld
frequent
driven
epsteinebarr
viru
ebv
seen
follow
form
transplant
increas
central
nervou
system
ebv
report
tradit
treatment
involv
remov
immunosuppress
may
mean
sacrif
organ
transplant
therapi
includ
rituximab
recent
avail
ebvspecif
cytotox
tcell
infus
prospect
effect
ebv
vaccin
improv
outcom
major
burden
invas
fungal
diseas
associ
defect
cmi
twothird
patient
invas
aspergillosi
neutropen
onset
seen
around
day
follow
stemcel
transplant
sct
usual
context
ongo
immunosuppress
immun
dysregul
hypogammaglobulinaemia
infrequ
seen
follow
transplant
certain
haematolog
malign
chronic
lymphocyt
leukaemia
immunoglobulin
v
h
chain
mutat
lead
function
disord
immunoglobulin
subclass
defici
recogn
follow
sct
complement
defici
also
occur
risk
overwhelm
infect
capsul
bacteria
streptococcu
pneumonia
haemophilu
influenza
type
b
neisseria
meningitidi
certain
strain
escherichia
coli
persist
indefinit
immunoglobulin
replac
therapi
immun
use
conjug
vaccin
antibiot
prophylaxi
may
warrant
opportunist
infect
often
gone
undiagnos
tradit
method
alway
distinguish
colon
contamin
true
infect
blood
cultur
sampl
steril
site
remain
use
tool
investig
neutropen
fever
posit
diagnost
yield
often
low
rapid
molecular
mass
spectroscop
techniqu
improv
sensit
markedli
problem
interpret
remain
diagnost
test
clinician
must
consid
want
test
result
diagnos
opportunist
infect
screen
test
rule
diagnosi
rather
test
rule
specif
infect
may
use
allow
empir
treatment
safe
withheld
sensit
assay
import
situat
often
expens
specif
pretest
probabl
diseas
like
low
result
falseposit
result
approach
may
still
superior
empir
therapi
specimen
type
import
specimen
difficult
obtain
requir
invas
techniqu
tissu
biopsi
lavag
fluid
suitabl
part
screen
gener
obtain
clinic
sign
suggest
abnorm
justifi
higher
pretest
probabl
diseas
molecular
test
regard
diagnost
specif
import
order
maxim
posit
predict
valu
test
may
better
util
prognost
assay
quantit
monitor
respons
treatment
efficaci
prophylaxi
healthcar
provid
endeavour
ensur
new
assay
rigor
assess
respect
analyt
valid
clinic
valid
clinic
util
econom
benefit
molecular
test
interpret
clinic
signific
may
complex
introduct
novel
multiplex
target
new
detect
platform
provid
inform
infecti
agent
whose
pathogen
potenti
sometim
unclear
exampl
whilst
appreci
signific
influenza
b
viru
respiratori
syncyti
viru
parainfluenza
virus
morbid
attribut
mortal
associ
metapneumoviru
coronaviru
rhinoviru
bocaviru
parainfluenza
importantli
dual
infect
pathogen
remain
fulli
elucid
differ
patient
group
similarli
multiplex
gastrointestin
panel
may
includ
novel
target
sapoviru
dientamoeba
sp
noroviru
even
known
opportunist
pathogen
level
detect
sensit
patient
may
remain
posit
prolong
period
whilst
otherwis
asymptomat
seriou
infect
control
implic
healthcar
provid
may
also
impact
patient
manag
caus
delay
treatment
andor
transplant
valid
algorithm
test
interpret
result
need
develop
quinolon
prophylaxi
fallen
favour
due
concern
regard
risk
clostridium
difficil
infect
recommend
nice
guidanc
highrisk
acut
leukaemia
stem
cell
transplant
solid
tumour
recommend
support
metaanalys
full
health
econom
analysi
show
reduc
shortterm
mortal
incid
neutropen
sepsi
outweigh
potenti
emerg
antibiot
resist
costeffect
intervent
patient
solid
tumour
howev
ongo
surveil
c
difficil
infect
requir
cancer
transplant
patient
remain
increas
risk
grow
spectrum
opportunist
pathogen
combin
insult
underli
diseas
newer
treatment
modal
recurr
infect
lead
profound
prolong
immunoparesi
major
advanc
made
molecular
diagnosi
allow
move
away
empir
therapi
refractori
fever
howev
diagnost
accuraci
fix
featur
specif
test
rather
reflect
test
use
particular
patient
popul
understand
test
perform
differ
group
fundament
maxim
clinic
benefit
improv
diagnost
method
practic
point
c
neutropen
fever
requir
prompt
initi
treatment
piperacillin
tazobactam
c
empir
aminoglycosid
glycopeptid
indic
c
modif
initi
empir
antibacteri
treatment
fever
clinic
diagnost
driven
base
sole
persist
fever
c
prophylaxi
quinolon
indic
highrisk
group
c
new
molecular
diagnost
test
requir
interpret
clinic
valu
use
influenc
patient
manag
unless
patient
specif
local
microbiolog
contraind
eg
penicillin
allergi
local
antimicrobi
resist
pattern
